Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.31 USD | -2.00% | -5.19% | -22.51% |
Financials (USD)
Sales 2024 * | 538K | Sales 2025 * | 675K | Capitalization | 24.6M |
---|---|---|---|---|---|
Net income 2024 * | -37M | Net income 2025 * | -48M | EV / Sales 2024 * | 45.8 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 36.4 x |
P/E ratio 2024 * |
-0.78
x | P/E ratio 2025 * |
-0.98
x | Employees | 29 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 90.77% |
Latest transcript on Oncternal Therapeutics, Inc.
1 day | -2.00% | ||
1 week | -5.19% | ||
1 month | -7.66% | ||
3 months | -14.94% | ||
6 months | +22.42% | ||
Current year | -22.51% |
Managers | Title | Age | Since |
---|---|---|---|
James Breitmeyer
FOU | Founder | 70 | 96-12-31 |
Richard Vincent
DFI | Director of Finance/CFO | 61 | 17-03-31 |
Salim Yazji
CTO | Chief Tech/Sci/R&D Officer | 55 | 21-05-16 |
Members of the board | Title | Age | Since |
---|---|---|---|
David Hale
FOU | Founder | 75 | 96-12-31 |
Dan Kisner
BRD | Director/Board Member | 77 | 19-06-06 |
Rosemary Mazanet
BRD | Director/Board Member | 67 | 21-01-26 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 8.31 | -2.00% | 2,594 |
24-04-29 | 8.48 | +2.29% | 2,659 |
24-04-26 | 8.29 | +0.48% | 1,441 |
24-04-25 | 8.25 | -3.45% | 6,862 |
24-04-24 | 8.545 | -2.51% | 1,600 |
Delayed Quote Nasdaq, April 30, 2024 at 04:30 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-22.51% | 24.6M | |
+0.17% | 42.19B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+5.23% | 24.63B | |
-24.79% | 18.2B | |
+26.69% | 12.01B | |
-3.13% | 11.76B | |
+6.57% | 10.4B | |
-18.08% | 9.94B |
- Stock Market
- Equities
- ONCT Stock